The estimated Net Worth of Kush Parmar is at least 47 百万$ dollars as of 29 December 2020. Kush Parmar owns over 470,000 units of Homology Medicines Inc stock worth over 913,681$ and over the last 8 years he sold FIXX stock worth over 45,822,163$. In addition, he makes 262,648$ as Independent Director at Homology Medicines Inc.
Kush has made over 8 trades of the Homology Medicines Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 470,000 units of FIXX stock worth 8,460,000$ on 29 December 2020.
The largest trade he's ever made was selling 615,000 units of Homology Medicines Inc stock on 16 May 2019 worth over 13,204,050$. On average, Kush trades about 122,928 units every 32 days since 2016. As of 29 December 2020 he still owns at least 982,453 units of Homology Medicines Inc stock.
You can see the complete history of Kush Parmar stock trades at the bottom of the page.
Dr. Kush M. Parmar M.D. serves as Independent Director of the Company. He is the Independent Director of the company. Dr. Parmar is a Managing Partner at 5AM Venture Management LLC, an early stage venture capital firm focused on the life sciences, where he has been since 2010. Before joining 5AM, from 2002 to 2010, he was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. physician scientist fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar currently serves on the boards of numerous private companies. He previously served as a board member or observer for Arvinas, Inc., Achaogen, Inc., Audentes Therapeutics, Inc. (acquired by Astellas Pharma Inc.), Pulmatrix, Inc. and scPharmaceuticals Inc. He is a member of the scientific advisory boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation, and is a fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals, attended courses at Harvard Business School and consulted for an oncology startup. He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Parmar’s experience in the life sciences industry,
As the Independent Director of Homology Medicines Inc, the total compensation of Kush Parmar at Homology Medicines Inc is 262,648$. There are 8 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of 5,062,880$.
Kush Parmar is 39, he's been the Independent Director of Homology Medicines Inc since 2015. There are 18 older and no younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
Kush's mailing address filed with the SEC is 2400 District Ave #310, Burlington, MA 01803, USA.
Over the last 7 years, insiders at Homology Medicines Inc have traded over 108,214,465$ worth of Homology Medicines Inc stock and bought 3,033,333 units worth 51,999,993$ . The most active insiders traders include Steven Gillis、James Edeerfield Management...、Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of 106,785$. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth 21,883$.
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Homology Medicines Inc executives and other stock owners filed with the SEC include: